In-vitro Diagnostics (IVD) Market Size, Share, Future Analysis, 2026-2034
Market Overview
According to fortune business insights, the global in-vitro diagnostics (IVD) market size is witnessing steady growth, driven by the increasing prevalence of infectious and chronic diseases, rising demand for early disease detection, and continuous advancements in diagnostic technologies. According to Fortune Business Insights, the global in-vitro diagnostics market was valued at USD 77.73 billion in 2025 and is projected to grow from USD 81.83 billion in 2026 to USD 135.65 billion by 2034, registering a CAGR of 6.50% during the forecast period (2026–2034). North America dominated the global market with a 37.70% share in 2025.
In-vitro diagnostics refers to medical tests performed on biological samples, including blood, urine, saliva, and tissue, outside the human body. These tests help healthcare professionals detect, diagnose, monitor, and manage various medical conditions. They play a crucial role in identifying infectious diseases, cardiovascular disorders, cancer, autoimmune conditions, and other health complications. Increasing investments in research and development, growing awareness regarding preventive healthcare, and the adoption of personalized medicine are further supporting market expansion.
Major Players Profiled
Key companies operating in the global in-vitro diagnostics market include:
F. Hoffmann-La Roche Ltd.
Abbott
Siemens Healthineers AG
Danaher Corporation
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company (BD)
bioMérieux SA
Bio-Rad Laboratories, Inc.
Sysmex Corporation
QIAGEN N.V.
These companies are focusing on product innovation, strategic collaborations, acquisitions, and technological advancements to strengthen their market positions.
Market Segmentation
The market is segmented based on product type, technique, sample, setting, application, and end-user.
By Product Type: Instruments and reagents & consumables. Reagents & consumables are expected to dominate with an 83.14% market share in 2026, supported by increasing testing volumes and demand for diagnostic kits.
By Technique: Immunodiagnostics, clinical chemistry, molecular diagnostics, hematology, and others. Molecular diagnostics is projected to account for 30.54% of the market in 2026.
By Sample: Blood, urine, saliva, tissue, and others. Blood samples are expected to dominate with a 33.24% share in 2026.
By Setting: Laboratories and point-of-care testing.
By Application: Infectious diseases, cardiology, oncology, gastroenterology, allergy, autoimmunity, prenatal screening, and others. Infectious diseases are projected to hold a 32.34% share in 2026.
By End-user: Clinical laboratories, hospitals, physician's offices, and others.
For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-ivd-market-101443
Market Drivers and Restraints
Market Drivers
The increasing prevalence of chronic and infectious diseases is a major factor driving market growth. Rising cases of cardiovascular disorders, cancer, diabetes, tuberculosis, and other health conditions are increasing the demand for accurate and timely diagnostic testing. Additionally, growing government support, healthcare expenditure, and investments in diagnostic research and development are encouraging the adoption of advanced IVD technologies.
Market Restraints
The high cost of diagnostic instruments, installation, and maintenance is restricting market penetration, particularly in developing economies. Advanced diagnostic systems also require trained professionals, increasing operational expenses. Furthermore, unfavorable reimbursement policies and complex regulatory requirements can delay product approvals and limit the adoption of innovative testing solutions.
Regional Insights
North America: North America dominated the global market with a 37.70% share in 2025, valued at USD 29.33 billion. The regional market is projected to reach USD 30.92 billion in 2026. Strong healthcare infrastructure, favorable reimbursement policies, technological advancements, and the presence of major diagnostic companies are supporting regional growth. The U.S. market is expected to reach USD 27.98 billion in 2026.
Europe: Europe accounted for 26.30% of the global market in 2025, reaching USD 20.46 billion. The market is projected to grow to USD 21.50 billion in 2026. Increasing healthcare expenditure, advanced diagnostic infrastructure, and rising adoption of molecular diagnostics are contributing to regional expansion. Germany remains a prominent market, while the U.K. and France are also witnessing increasing demand.
Asia Pacific: Asia Pacific accounted for 23.00% of the global market in 2025, valued at USD 17.86 billion, and is expected to reach USD 18.94 billion in 2026. Increasing healthcare investments, rising disease prevalence, and improving diagnostic infrastructure across India, China, Japan, and South Korea are driving market growth. China's market is projected to reach USD 6.61 billion in 2026, while India's market is expected to reach USD 3.37 billion.
Latin America: The market reached USD 5.99 billion in 2025, representing 7.70% of global revenue, and is projected to reach USD 6.22 billion in 2026. Growing healthcare expenditure, an aging population, and increasing adoption of point-of-care diagnostic devices are supporting regional development.
Middle East & Africa: The market was valued at USD 4.11 billion in 2025, accounting for 5.30% of global revenue, and is expected to reach USD 4.25 billion in 2026. Healthcare infrastructure development, strategic acquisitions, and increasing investments in diagnostic facilities are creating growth opportunities.
Future Growth Trends
The IVD market is expected to experience sustained growth through 2034, supported by technological innovation and increasing demand for efficient diagnostic solutions. The growing adoption of molecular diagnostics, next-generation sequencing, and point-of-care testing is transforming disease detection and monitoring.
Furthermore, the integration of artificial intelligence (AI), automation, and machine learning into diagnostic instruments is improving testing accuracy, operational efficiency, and laboratory productivity. Personalized medicine and biomarker-based testing are also gaining importance, enabling healthcare professionals to develop more targeted treatment approaches.
The rising demand for decentralized testing, rapid diagnostic kits, and self-testing solutions is expected to create additional opportunities for manufacturers. Strategic collaborations, product launches, and investments in research and development will further strengthen the industry's growth prospects.
Competitive Landscape
The global in-vitro diagnostics market is semi-consolidated, with leading companies focusing on technological innovation, product portfolio expansion, strategic partnerships, and acquisitions. F. Hoffmann-La Roche Ltd., Abbott, and Siemens Healthineers AG are among the prominent market participants. Other important companies include Thermo Fisher Scientific Inc., Sysmex Corporation, BD, Seegene Inc., DiaSorin S.p.A., Quest Diagnostics Incorporated, and Bio-Rad Laboratories, Inc.
Companies are increasingly investing in advanced diagnostic platforms, molecular testing solutions, and automated laboratory systems to strengthen their competitive positions and expand their global presence.
Key Industry Developments
February 2024: Thermo Fisher Scientific Inc. launched a new ion chromatography instrument to improve laboratory reliability, efficiency, and functional adaptability.
December 2023: Thermo Fisher Scientific Inc. signed a distribution agreement with AESKU GROUP GmbH to market IFA testing kits and instruments in the U.S.
December 2023: Sysmex Corporation received insurance coverage for its HISCL M2BPGi-Qt Assay Kit for chronic hepatitis testing.
November 2023: Abbott received U.S. FDA approval for its molecular HPV screening solution, expanding its Alinity m diagnostic assay portfolio.
May 2023: Siemens Healthineers AG launched its next-generation Atellica HEMA 570 and 580 hematology analyzers.
Comments